Max Healthcare Institute Ltd
Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and related healthcare services. [1]
- Market Cap ₹ 1,06,776 Cr.
- Current Price ₹ 1,098
- High / Low ₹ 1,314 / 936
- Stock P/E 140
- Book Value ₹ 85.3
- Dividend Yield 0.14 %
- ROCE 12.5 %
- ROE 9.45 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 203% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 18.7%
Cons
- Stock is trading at 12.9 times its book value
- Company has a low return on equity of 9.70% over last 3 years.
- Earnings include an other income of Rs.330 Cr.
- Debtor days have increased from 33.1 to 40.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 591 | 790 | 912 | 984 | 1,059 | 1,008 | 59 | 1,031 | 1,775 | 1,905 | 2,341 | 2,664 | 2,736 | |
| 615 | 768 | 890 | 941 | 1,048 | 976 | 65 | 870 | 1,332 | 1,321 | 1,579 | 1,830 | 1,913 | |
| Operating Profit | -24 | 22 | 22 | 43 | 11 | 31 | -6 | 161 | 443 | 584 | 762 | 833 | 823 |
| OPM % | -4% | 3% | 2% | 4% | 1% | 3% | -10% | 16% | 25% | 31% | 33% | 31% | 30% |
| 39 | 33 | 35 | 30 | 51 | 47 | 66 | -104 | 128 | 144 | 271 | 293 | 330 | |
| Interest | 42 | 43 | 30 | 35 | 41 | 44 | 60 | 112 | 59 | 52 | 52 | 48 | 50 |
| Depreciation | 31 | 49 | 50 | 51 | 49 | 53 | 3 | 91 | 112 | 113 | 117 | 131 | 136 |
| Profit before tax | -58 | -38 | -24 | -13 | -28 | -18 | -3 | -146 | 400 | 563 | 865 | 947 | 966 |
| Tax % | 0% | 0% | -0% | 0% | 0% | 26% | -5% | 12% | 17% | -23% | 21% | 26% | |
| -58 | -38 | -24 | -13 | -28 | -23 | -3 | -164 | 332 | 694 | 687 | 701 | 713 | |
| EPS in Rs | -1.46 | -0.78 | -0.44 | -0.24 | -0.51 | -0.43 | -0.06 | -1.70 | 3.42 | 7.15 | 7.07 | 7.21 | 7.33 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 14% | 21% | 21% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 114% |
| 3 Years: | 14% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 203% |
| 3 Years: | 32% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 55% |
| 3 Years: | 35% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 395 | 489 | 533 | 537 | 537 | 537 | 537 | 966 | 970 | 971 | 972 | 972 |
| Reserves | 167 | 523 | 762 | 770 | 773 | 749 | 2,338 | 4,973 | 5,342 | 6,071 | 6,709 | 7,317 |
| 505 | 296 | 273 | 314 | 386 | 390 | 658 | 480 | 556 | 534 | 443 | 612 | |
| 223 | 141 | 171 | 210 | 278 | 274 | 20 | 724 | 945 | 845 | 945 | 1,065 | |
| Total Liabilities | 1,290 | 1,449 | 1,740 | 1,832 | 1,973 | 1,951 | 3,553 | 7,143 | 7,812 | 8,420 | 9,069 | 9,967 |
| 468 | 430 | 424 | 429 | 502 | 479 | 90 | 2,989 | 4,493 | 4,485 | 4,717 | 4,871 | |
| CWIP | 10 | 15 | 6 | 30 | 7 | 10 | 0 | 8 | 60 | 103 | 235 | 277 |
| Investments | 238 | 451 | 840 | 866 | 799 | 770 | 2,471 | 2,379 | 1,447 | 1,475 | 1,915 | 2,614 |
| 574 | 554 | 469 | 508 | 665 | 693 | 992 | 1,766 | 1,811 | 2,358 | 2,202 | 2,206 | |
| Total Assets | 1,290 | 1,449 | 1,740 | 1,832 | 1,973 | 1,951 | 3,553 | 7,143 | 7,812 | 8,420 | 9,069 | 9,967 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39 | 64 | 33 | 52 | -19 | -36 | 219 | 447 | 696 | 613 | 598 | ||
| -200 | -330 | -66 | -89 | 55 | -2,536 | -84 | -670 | -843 | -806 | -873 | ||
| 176 | 251 | 34 | 36 | -36 | 2,332 | 397 | -161 | -54 | -246 | -29 | ||
| Net Cash Flow | 15 | -16 | 0 | -0 | -0 | -240 | 532 | -384 | -201 | -438 | -304 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 67 | 48 | 55 | 68 | 103 | 517 | 109 | 56 | 27 | 32 | 40 |
| Inventory Days | 18 | 20 | 18 | 19 | 22 | 25 | 33 | 20 | 31 | 24 | 20 | |
| Days Payable | 158 | 171 | 183 | 206 | 250 | 335 | 297 | 159 | 226 | 225 | 191 | |
| Cash Conversion Cycle | -42 | -85 | -117 | -132 | -161 | -206 | 517 | -155 | -83 | -169 | -169 | -130 |
| Working Capital Days | -54 | -15 | -33 | -20 | -27 | 14 | -493 | 27 | 5 | -45 | -32 | -24 |
| ROCE % | 0% | 1% | 1% | 2% | 2% | 4% | 7% | 9% | 12% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
24m - Max Healthcare: CLSA India Forum Nov 18; Goldman Sachs CIO Tour Nov 20, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Nov - Schedule of Earnings Call for Investors and Analysts
-
Board Meeting Intimation for Consideration And Approval Of Financial Results
8 Nov - Board meeting on Nov 14, 2025 to approve Q2/H1 results ended Sep 30, 2025, trading window closed until 48 hours post-declaration.
-
Approval Of Scheme Of Amalgamation Between Crosslay Remedies Limited And Jaypee Healthcare Limited
7 Nov - NCLT sanctioned Crosslay Remedies merging into Jaypee Healthcare; Order dated Nov 7, 2025; Appointed Date Oct 5, 2024.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
7 Nov - SES assigned ESG score 75.1 for FY2024-25 (up from 73.7); notified Nov 6, 2025.
Annual reports
Concalls
-
Aug 2025Transcript PPT REC
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT REC
-
Jan 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT REC
-
Nov 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
May 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
Leadership
The company is India’s 2nd largest hospital chain in terms of hospital revenue, EBITDA, and market capitalization. [1]